脂基纳米载体局部治疗皮肤利什曼病:对作用机制的洞察

IF 4.3 3区 化学 Q2 CHEMISTRY, MULTIDISCIPLINARY
Amina Riaz, Muhammad Farhan Ali Khan, Aamir Jalil, Asim ur Rehman, Naveed Ahmed, Zobia Mubarak, Maryam Parhizkar* and Hira Muqaddas, 
{"title":"脂基纳米载体局部治疗皮肤利什曼病:对作用机制的洞察","authors":"Amina Riaz,&nbsp;Muhammad Farhan Ali Khan,&nbsp;Aamir Jalil,&nbsp;Asim ur Rehman,&nbsp;Naveed Ahmed,&nbsp;Zobia Mubarak,&nbsp;Maryam Parhizkar* and Hira Muqaddas,&nbsp;","doi":"10.1021/acsomega.5c0004610.1021/acsomega.5c00046","DOIUrl":null,"url":null,"abstract":"<p >Cutaneous leishmaniasis (CL) is a parasitic infection caused by Leishmania species, affecting millions worldwide. The current treatment options for CL have several limitations, including low efficacy, inability to reach the target site, potential toxicity, and longer treatment duration, leading to poor patient compliance. Therefore, there is an urgent need for alternative treatments, especially topical ones, that are more effective, safe, and patient-friendly. Although numerous reviews have described the advantages of a wide range of nanoparticles in the treatment of CL, this review narrows its focus to the utilization of novel lipid-based nanocarriers for the topical treatment of CL, offering an in-depth analysis of the topical potential and mechanism of skin permeation of these lipidic nanocarriers. Lipid-based nanostructures such as liposomes, solid lipid nanoparticles, and nanostructured lipid carriers have been extensively studied for CL treatment, either alone or in combination with other drugs or therapies. These carriers can improve the bioavailability, stability, and efficacy of the drug, target the infected site, and reduce adverse effects on healthy tissues. Moreover, these can be easily formulated into different dosage forms, such as creams, gels, or ointments, for convenient topical application. Despite the many benefits of lipid-based carriers, there are still some challenges that need to be addressed, such as optimizing the formulation parameters, ensuring the reproducibility and scalability of the process, and evaluating the long-term safety and efficacy in clinical trials. This study aims to provide a comprehensive overview of the current state-of-the-art lipid-based nanocarriers for topical treatment of CL, covering the recent advances, limitations, clinical evidence, and prospects of this promising approach. In addition, the skin and macrophage targeting potential of various lipid-based nanocarriers is also discussed, which is especially helpful in treating the lesions of CL.</p>","PeriodicalId":22,"journal":{"name":"ACS Omega","volume":"10 23","pages":"23873–23888 23873–23888"},"PeriodicalIF":4.3000,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.acs.org/doi/epdf/10.1021/acsomega.5c00046","citationCount":"0","resultStr":"{\"title\":\"Lipid-Based Nanocarriers for Topical Therapy of Cutaneous Leishmaniasis: An Insight into the Mechanism of Action\",\"authors\":\"Amina Riaz,&nbsp;Muhammad Farhan Ali Khan,&nbsp;Aamir Jalil,&nbsp;Asim ur Rehman,&nbsp;Naveed Ahmed,&nbsp;Zobia Mubarak,&nbsp;Maryam Parhizkar* and Hira Muqaddas,&nbsp;\",\"doi\":\"10.1021/acsomega.5c0004610.1021/acsomega.5c00046\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p >Cutaneous leishmaniasis (CL) is a parasitic infection caused by Leishmania species, affecting millions worldwide. The current treatment options for CL have several limitations, including low efficacy, inability to reach the target site, potential toxicity, and longer treatment duration, leading to poor patient compliance. Therefore, there is an urgent need for alternative treatments, especially topical ones, that are more effective, safe, and patient-friendly. Although numerous reviews have described the advantages of a wide range of nanoparticles in the treatment of CL, this review narrows its focus to the utilization of novel lipid-based nanocarriers for the topical treatment of CL, offering an in-depth analysis of the topical potential and mechanism of skin permeation of these lipidic nanocarriers. Lipid-based nanostructures such as liposomes, solid lipid nanoparticles, and nanostructured lipid carriers have been extensively studied for CL treatment, either alone or in combination with other drugs or therapies. These carriers can improve the bioavailability, stability, and efficacy of the drug, target the infected site, and reduce adverse effects on healthy tissues. Moreover, these can be easily formulated into different dosage forms, such as creams, gels, or ointments, for convenient topical application. Despite the many benefits of lipid-based carriers, there are still some challenges that need to be addressed, such as optimizing the formulation parameters, ensuring the reproducibility and scalability of the process, and evaluating the long-term safety and efficacy in clinical trials. This study aims to provide a comprehensive overview of the current state-of-the-art lipid-based nanocarriers for topical treatment of CL, covering the recent advances, limitations, clinical evidence, and prospects of this promising approach. In addition, the skin and macrophage targeting potential of various lipid-based nanocarriers is also discussed, which is especially helpful in treating the lesions of CL.</p>\",\"PeriodicalId\":22,\"journal\":{\"name\":\"ACS Omega\",\"volume\":\"10 23\",\"pages\":\"23873–23888 23873–23888\"},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2025-06-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://pubs.acs.org/doi/epdf/10.1021/acsomega.5c00046\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACS Omega\",\"FirstCategoryId\":\"92\",\"ListUrlMain\":\"https://pubs.acs.org/doi/10.1021/acsomega.5c00046\",\"RegionNum\":3,\"RegionCategory\":\"化学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CHEMISTRY, MULTIDISCIPLINARY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Omega","FirstCategoryId":"92","ListUrlMain":"https://pubs.acs.org/doi/10.1021/acsomega.5c00046","RegionNum":3,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
引用次数: 0

摘要

皮肤利什曼病(CL)是一种由利什曼原虫引起的寄生虫感染,影响全世界数百万人。目前CL的治疗方案存在一些局限性,包括疗效低、无法到达靶部位、潜在毒性和治疗时间较长,导致患者依从性差。因此,迫切需要一种更有效、更安全、对患者更友好的替代治疗,特别是局部治疗。尽管许多文献已经描述了广泛的纳米颗粒在治疗CL方面的优势,但本综述将重点集中在新型脂质纳米载体在局部治疗CL方面的应用上,并深入分析了这些脂质纳米载体的局部潜力和皮肤渗透机制。基于脂质的纳米结构,如脂质体、固体脂质纳米颗粒和纳米结构脂质载体,无论是单独治疗还是与其他药物或疗法联合治疗,都已被广泛研究。这些载体可以提高药物的生物利用度、稳定性和疗效,靶向感染部位,减少对健康组织的不良影响。此外,这些可以很容易地配制成不同的剂型,例如乳霜、凝胶或软膏,以方便局部应用。尽管脂质载体有许多优点,但仍有一些挑战需要解决,如优化配方参数,确保工艺的可重复性和可扩展性,以及在临床试验中评估长期安全性和有效性。本研究旨在全面概述目前最先进的脂质纳米载体用于局部治疗CL,包括最近的进展、局限性、临床证据和前景。此外,还讨论了各种脂质纳米载体的皮肤和巨噬细胞靶向潜力,这对治疗CL病变特别有帮助。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Lipid-Based Nanocarriers for Topical Therapy of Cutaneous Leishmaniasis: An Insight into the Mechanism of Action

Cutaneous leishmaniasis (CL) is a parasitic infection caused by Leishmania species, affecting millions worldwide. The current treatment options for CL have several limitations, including low efficacy, inability to reach the target site, potential toxicity, and longer treatment duration, leading to poor patient compliance. Therefore, there is an urgent need for alternative treatments, especially topical ones, that are more effective, safe, and patient-friendly. Although numerous reviews have described the advantages of a wide range of nanoparticles in the treatment of CL, this review narrows its focus to the utilization of novel lipid-based nanocarriers for the topical treatment of CL, offering an in-depth analysis of the topical potential and mechanism of skin permeation of these lipidic nanocarriers. Lipid-based nanostructures such as liposomes, solid lipid nanoparticles, and nanostructured lipid carriers have been extensively studied for CL treatment, either alone or in combination with other drugs or therapies. These carriers can improve the bioavailability, stability, and efficacy of the drug, target the infected site, and reduce adverse effects on healthy tissues. Moreover, these can be easily formulated into different dosage forms, such as creams, gels, or ointments, for convenient topical application. Despite the many benefits of lipid-based carriers, there are still some challenges that need to be addressed, such as optimizing the formulation parameters, ensuring the reproducibility and scalability of the process, and evaluating the long-term safety and efficacy in clinical trials. This study aims to provide a comprehensive overview of the current state-of-the-art lipid-based nanocarriers for topical treatment of CL, covering the recent advances, limitations, clinical evidence, and prospects of this promising approach. In addition, the skin and macrophage targeting potential of various lipid-based nanocarriers is also discussed, which is especially helpful in treating the lesions of CL.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
ACS Omega
ACS Omega Chemical Engineering-General Chemical Engineering
CiteScore
6.60
自引率
4.90%
发文量
3945
审稿时长
2.4 months
期刊介绍: ACS Omega is an open-access global publication for scientific articles that describe new findings in chemistry and interfacing areas of science, without any perceived evaluation of immediate impact.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信